Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Feb 08, 2023 11:39am
170 Views
Post# 35274568

RE:RE:Pfizer in court over Chinese stealing trade secrets

RE:RE:Pfizer in court over Chinese stealing trade secrets"In its original lawsuit, Pfizer accused Zhong and Qiu of setting up Regor while still working at Pfizer and “stealing the hard work of Pfizer’s scientists and clinicians for their own profit and gain.” Pfizer claimed Regor pinched information from a confidential presentation on its GLP-1 program for diabetes and obesity to help build out the biotech and secure patents."

The complaint alleged that Qiu and Zhong misappropriated trade secrets in violation of the Defend Trade Secrets Act as well as Connecticut trade secret laws.


Qiu served as executive director of structural biology at Pfizer-Connecticut, where he led as many as 60 scientists through drug discovery efforts. His group contributed to 29 clinical candidates. Qiu also served on expert review panels for the National Institutes of Health.

Zhong spent 19 years in Pfizer’s R&D organization, most recently as director of pharmacokinetics, dynamics and metabolism (PDM) and head of its external research solutions group, according to the complaint. In that role, he was responsible for business development for Pfizer’s worldwide R&D external research portfolios as well as scientific/compliance oversight for the PDM group’s regulatory submissions.

<< Previous
Bullboard Posts
Next >>